The First Fully Personalized, Demographic-Specific Drug Platform
CoreX develops new drugs. Reinvents old ones. Powered by AI and personalized stem cell–derived organoids.
What is CoreX?
We've spent 4 years and $50M building the only globally validated platform that turns a simple blood draw into fully personalized, population-specific drug development and optimization data—using AI and personalized organoids to reinvent both new and existing medicines. Validated by top-tier pharma - Now we're bringing it to the UAE.
Sovereign Impact:
CoreX enables Abu Dhabi to build a sovereign personalized drug development engine, positioning the UAE as a global leader in precision health and longevity medicine—backed by the full weight of its sovereign wealth ecosystem.
Unmatched Opportunity:
  • $650B+ Market Tidal Wave: AI drug discovery: $50B+ by 2030, longevity & precision medicine: $600B+ by 2030
  • Recent FDA Roadmap mandates replacing animal testing within 3-5 years; CoreX is the only scalable, compliant solution.
  • Anchored by exclusive technology, molecule pipeline, 18 patents, and strategic partnerships with world leaders in stem cell and AI medicine, valued at $400M.
  • Targets a $3B+ strategic exit in 36 months, with a 6–9x return for those who move before the sovereign anchor round closes.
Dual Superpowers & Boardroom Power
Our Dual Superpowers: "Optimize" and "Innovate" Strategies
Optimize
  • Optimize existing pipeline drugs, tailoring and personalizing them to demographic specific safety and efficacy.
  • Identify hidden PK/PD risks and unlock new value from legacy molecules.
  • AI screens thousands of molecules; iPSCs from local blood samples generate personalized mini-organs for "clinical trials on a chip."
  • Safer, more effective, and faster-to-market—optimized for populations such as Emiratis from day one.
Innovate
  • Develop new drugs from scratch, tailored for each demographic.
  • Tweak existing drugs, creating and patenting novel drugs that are optimized for Emirati sub-populations.
Boardroom Power & Strategic Edge
Board of Titans:
CoreX's board and advisory includes a Nobel Laureate, ex-global pharma CEOs, and regional sovereign champions—offering unrivaled access, global validation, and execution muscle.
Sovereign Advantage:
Full local control of biology and data, perpetual IP protection, and rapid molecule development in priority areas—anchored by UAE's sovereign wealth ecosystem.
Global Recognition:
#1 in AI–Longevity and Drug Safety (Frost & Sullivan), SCRIP Innovation Award, exclusive MIT-based iPSC liver-on-chip license, and the world's largest organ-chip data base.
Investment Opportunity: Scarcity, Speed & Sovereign Upside
50% of this $100M round already soft-circled to sovereign and strategic partners
The Population BioLibrary:
Abu Dhabi's living, renewable biobank of iPSCs and personalized organoids—sovereign control, perpetual innovation, and a national health security asset.
Superpowered Sovereign Institutions:
Backed by UAE's sovereign wealth ecosystem, CoreX is the strategic cornerstone of the region's biotech future.
Time-Boxed:
50% of this round is already soft-circled to sovereign and strategic partners. The final allocation is expected to close July 30, 2025.
Contact:
Sarah Miller
056 222 3782
sarah@lifex.ai